Why the study?
Little is known regarding antithrombotic prescribing in U.S. hospice patients.
What is the prevalence and what are the predictors of receiving an antithrombotic prescription on hospice admission in adult hospice patients?
Population
54,643 adult decedents of a large for-profit hospice chain who died between 2017 and 2019
Comparison
Receiving vs not receiving an antithrombotic prescription on hospice admission
Design
Cross-sectional study
Authors
Loading...
May prompt careful review rather than automatic deprescribing; leaves open the net benefit of antithrombotics in hospice.
What is the prevalence and what are the predictors of receiving an antithrombotic prescription on hospice admission in adult hospice patients?
Antithrombotic therapy remains highly prevalent upon hospice admission, particularly among patients with better functional status and those in non-inpatient care settings.
Short et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: